[11] 2020 also saw the company acquire property worth $25 million from Marcus Partners for the construction of a new 219,000 square foot laboratory building, after razing existing structures, located in the Raymond L Flynn Marine Park.

[14] On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform.

[18] On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.

The tool known as ENDAR (short for Engineered Nucleotide Detection and Ranking) could be used to provide an early warning of bioweapons and other man-made biological threats.

[23] On 6 October 2021, a market research firm published a report accusing Ginkgo of embellishing its revenue in a complex scheme highly dependent on related-party transactions.

[25] In November 2021, Ginkgo was sued in a shareholder lawsuit alleging it misrepresented its revenue sources in statements regarding its merger with a Special-purpose acquisition company.